ArticleCurrent treatment options in neurology2015
In search of a treatment for radiation-induced optic neuropathy.
Article in Current treatment options in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Correlation Between Endocrine and Other Clinical Factors with Peripapillary Retinal Nerve Fiber Layer Thickness After Surgical Treatment of Pediatric Craniopharyngioma.Biomedicines · 2026Article
- Article
- Article
- Neurologic Complications in Adult Cancer Survivorship.Seminars in neurology · 2024Article
- Review
- Surveillance of long-term complications after treatment of adult brain tumor survivors-review and evidence-based recommendations.Neuro-oncology practice · 2022Review
- Article
- Uveal melanoma diagnosis and current treatment options (Review).Experimental and therapeutic medicine · 2021Review
- Intracranial long-term complications of radiation therapy: an image-based review.Neuroradiology · 2021Review
- Radiation-Induced Optic Neuropathy: Literature Review.Neuro-ophthalmology (Aeolus Press) · 2021Review
- Cdk5-mediated Drp1 phosphorylation drives mitochondrial defects and neuronal apoptosis in radiation-induced optic neuropathy.Cell death & disease · 2020Article
- Catastrophic vision loss from radiation-induced optic neuropathy.BMJ case reports · 2020Article
- Predictors of the therapeutic effect of corticosteroids on radiation-induced optic neuropathy following nasopharyngeal carcinoma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Bilateral Radiation Optic Neuropathy Following Concurrent Chemotherapy and Radiation in Glioblastoma.Neuro-ophthalmology (Aeolus Press) · 2017Article
- Risk factors for radiation-induced optic neuropathy: a case-control study.Clinical & experimental ophthalmology · 2017Article
- Glaucomagenesis following ionizing radiation exposure.Mutation research. Reviews in mutation researchReview
- Anticoagulation for Radiation-Induced Optic Neuropathy.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementRadiation-induced optic neuropathy (RON) is an iatrogenic complication that causes severe, irreversible vision loss in one or both eyes within the months to years following radiation therapy. Posterior RON is a rare but devastating toxicity of radiation applied to the visual pathways to treat paranasal sinus and skull base tumors. Anterior RON is an unavoidable consequence of proton beam irradiation or ophthalmic plaque treatment of orbital, choroidal, or retinal tumors. Various treatments aimed at stabilizing and ideally reversing vision loss have been investigated but only in small cases series. Systemic corticosteroids and anticoagulants, which are moderately effective when used for cerebral radiation necrosis, have shown no signs of benefit for RON. Hyperbaric oxygen therapy may promote short-term, partial recovery of vision in select patients, especially at partial pressures of at least 2.4 atm and when administered early after symptom onset. Reversal of visual deficits through treatment with systemic bevacizumab has been reported, but until controlled studies are performed, the side effect profile of stroke and myocardial infarction should limit its use in a population with predisposing cardiovascular risk factors. Intravitreal bevacizumab has shown promising results in patients with anterior RON, but repeated, long-term injections are required for sustained effect. As no intervention has been clearly shown to halt or reverse vision loss, larger prospective studies are needed to validate observed benefits for any of the treatments that have been described.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.